Zymeworks
Manufacturing · Canada · 201-500 Employees
View Company Info for Free
Overview
Headquarters
114 E 4th Ave Ste 800, Vancouver, Britis...Phone Number
(604) 678-1388Website
www.zymeworks.comRevenue
$81.3 MillionStock Symbol
ZYMEIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
4
1
1
1
1
1
About Zymeworks
Zymeworks, founded in 2003 and based in Vancouver, BC, is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics.Explore more
Zymeworks Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Zymeworks your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Zymeworks
Product Launch: Get notified when Zymeworks launches new products
Zymeworks, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Zymeworks recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Zymeworks is spiking on competitors!
Check if Zymeworks has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Zymeworks has new funding data
Click to see if Zymeworks had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Zymeworks
Compare insights from companies similar to Zymeworks, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Zymeworks is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Zymeworks is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Zymeworks.
Zymeworks financials insights
Gather financial insights about Zymeworks, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Multiple Rounds
$22.3M
2015
Multiple Rounds
$34.4M
2016
Series A
$61.5M
2017
Stock Offering
$63.6M
2018
Stock Offering
$97.8M
2019
Stock Offering
$201.3M
2020
Stock Offering
$320.8M
Zymeworks Tech Stack
A closer look at the technologies used by Zymeworks
See more technologies
Most Recent Scoops
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Person-Based
Medical Research, Pharmaceuticals, Clinical Operations
Person-Based
Medical Research, Clinical Operations
Project
Zymeworks has announced that the IND filing for ZW1528, its IL-4/IL-33 bispecific antibody, has been delayed to 2027 as the team incorporates Phase III data from AstraZeneca, Roche, and Sanofi to refine the Phase I study design, including patient selection and COPD subgroup criteria.
Medical Research, Pharmaceuticals, Clinical Operations
Open Position
Zymeworks News & Media
Is Zymeworks Inc. (ZYME) Stock an Undervalued Biotech Opportunity With Oncology Growth Ahead?
We recently compiled a list of the 10 Best Biotech Stocks to Buy According to Analysts. Zymeworks Inc. (NASDAQ:ZYME) is one of the best biotech stocks on this list. TheFly reported on June 9 that Truist Securities initiated coverage of ZYME with a Buy rating and a $28 price target, down from $40. The firm highlighted ZYME […]Zymeworks agrees to buy Theravance Biopharma for $929m
The boards of both companies unanimously approved the agreement, which remains subject to shareholder and regulatory approvals.Zymeworks Inc. (ZYME) M&A Call Transcript
Zymeworks Inc. (ZYME) M&A Call June 29, 2026 8:30 AM EDTCompany ParticipantsShrinal Inamdar - VP of Investor RelationsKenneth Galbraith - Chairman of...THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT
Theravance Biopharma shareholders to receive $17.00 per share in cash, representing an equity value of approximately $929 million Theravance Biopharma shareholders to receive a contingent value right (CVR) entitling them to 80% of net proceeds from any future license, divestiture or other...
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Zymeworks
Sign Up For FreeTo access detailed company insights
Zymeworks, founded in 2003 and based in Vancouver, BC, is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics.... Read More
